A Phase 4 interventional study of Humatrope in Turner Syndrome, sponsored by Eli Lilly and Company. Completed at 9 sites in United States. Open to female participants aged 4 Years to 20 Years. Per ClinicalTrials.gov, last updated 2017-03-31.
Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing Human Growth Hormone in Turner Syndrome — none open to participants now, none under way, none of them phase 3. Human Growth Hormone · Turner Syndrome.
Among the 14 studies testing Human Growth Hormone in Turner Syndrome, this one is the 9th largest by enrollment, is one of 3 that started in 2005, is one of 6 in phase 4, and was the 6th registered.
125 studies on the registry are indexed under Turner Syndrome; 33 are open to participants now.
Browse Turner Syndrome studies →None of the 14 studies testing Human Growth Hormone in Turner Syndrome is open now. The open studies under Turner Syndrome, anywhere →
Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 25 Turner Syndrome studies recruiting now, 8 (32%) set no upper age limit and 14 (56%) stop at 75 or younger; 15 take children under 18; 5 take healthy volunteers.
This study: 4 Years to 20 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 1987; this study’s year is marked. 3 started in 2005.
This study's enrollment of 69 is close to the median of 67 across 52 interventional studies indexed under Turner Syndrome.
Median enrollment 108 across the 14 interventional studies. Of the 14 that completed or were terminated, 5 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 8 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 154 are open to participants now.
Of its 541 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
Eli Lilly and Company has 3 studies filed under Turner Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing Human Growth Hormone in Turner Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an extension study that will gather long-term data on the effect of early growth hormone (GH) treatment on adult height and other aspects of health and development in girls with Turner syndrome. The main purpose is to determine whether girls who received 2 years of GH treatment before 6 years of age achieve taller adult height than girls who were untreated during this time. The study will also look at middle ear and hearing function, and cognitive and behavioral development. Protocol completion is defined as attainment of height velocity less than or equal to 1.0 cm/year, or bone age greater than or equal to 15 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
No drug administration in B9R-US-GDFG (NCT00406926). Humatrope according to investigator's clinical practice and guided by the approved package insert on whether treatment is given.
Drug: Humatrope
Humatrope according to investigator's clinical practice and guided by the approved package insert on whether treatment is given.
Drug: Humatrope
According to investigator's clinical practice and guided by the approved package insert
Also known as: LY137998, Somatropin, Growth hormone
Most Mature Height Standard Deviation Score (SDS)
SDS reports the number of standard deviations from the mean for age and sex for an individual measurement (normal range is -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.
Time frame: Baseline through End of Study (10 years)
Height SDS at Various Ages
SDS reports the number of standard deviations from the mean for age and sex for an individual measurement (normal range is -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.
Time frame: Age 10, Age 13, Age 16
Age at Attainment of Tanner 2 Breast Development
The Tanner 2 breast development is the age at first evidence of breast development.
Time frame: Baseline through End of Study (10 years)
Chronological Age at First Visit Participant Attained Bone Age of 14.5 Years
Bone age was measured by standard radiograph, x-ray at baseline and annually for 10 years or until attainment of height velocity less than or equal to 1.0 centimeter per year (cm/year) and bone age greater or equal to 15 years.
Time frame: Baseline through End of Study (10 years)
Reports of Serious Adverse Events
Number of serious adverse events (SAEs) reported. Any adverse event from this study that results in one of the following outcomes, or is significant for any other reason were reported as an SAE: death, initial or prolonged inpatient hospitalization, a life-threatening experience (that is, immediate risk of dying), persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of a study subject, significant for any other reason (includes cancer, other than superficial, and basal cell or squamous cell carcinomas of the skin, that did not meet other serious adverse event criteria). A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.
Time frame: Baseline through End of Study (10 years)
Percentage of Participants With Occurrence of Pre-specified Clinically Relevant Events
Percentage of participants for whom certain non-serious, pre-specified adverse events (AEs; those that are commonly observed in Turner syndrome or are known to be related to GH treatment: impaired glucose tolerance, diabetes mellitus, hypothyroidism, benign intracranial hypertension, scoliosis, slipped capital femoral epiphysis, solid tumor/leukemia, pancreatitis, ear infections, and high blood pressure) are reported.
Time frame: Baseline through End of Study (10 years)
Percentage of Participants With Abnormal Tympanometry Results
Percentage of participants with abnormal tympanometry \[defined as middle ear dysfunction / middle ear effusion / patent pressure equalizer tube or possible tympanic membrane perforation\] results at baseline, age 10 years, and age 16 years or endpoint.
Time frame: Baseline, Age 10, Age 16, End of Study (10 years)
Percentage of Participants With Prevalence of Abnormal Audiometry Results
Percentage of participants with abnormal Audiometry results at baseline, age 10 years, and age 16 years or endpoint. Prevalence was calculated as number of participants with abnormal hearing divided by number of participants with measurable pure tone audiometry results at that visit.
Time frame: Baseline, Age 10, Age 16, End of Study (10 years)
Percentage of Participants With Abnormal Audiometry Results Based on Pure Tone Average (PTA)
Percentage of participants with abnormal Audiometry results at baseline, age 10 years, and age 16 years or endpoint. PTA is defined as the average of pure tone hearing thresholds at 500, 1000 and 2000 Hz (Hertz), calculated separately for each ear and for each testing method (air or bone); normal PTA is defined as pure tone hearing threshold less than or equal to 20 dB HL (decibels Hearing Level), and abnormal PTA is defined as pure tone hearing threshold greater than 20 DB HL.
Time frame: Baseline, Age 10, Age 16, End of Study (10 years)
To be included in this study, participants had to be females with karyotype-proven Turner syndrome who were previously randomized in Study B9R-US-GDFG (NCT00406926).
| Milestone | Early Treated | Early Untreated |
|---|---|---|
| Started | 36 | 33 |
| Completed | 22 | 20 |
| Not completed | 14 | 13 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lost to follow-up | 4 | 1 |
| Withdrew: Withdrawal by subject | 4 | 2 |
| Withdrew: Did not reach final height | 4 | 8 |
| Withdrew: Parent/caregiver decision | 1 | 2 |
SDS reports the number of standard deviations from the mean for age and sex for an individual measurement (normal range is -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.
| standard deviation score | Early Treated | Early Untreated |
|---|---|---|
| Most Mature Height Standard Deviation Score (SDS) | -1.37 ± 1.09 | -1.60 ± 1.21 |
SDS reports the number of standard deviations from the mean for age and sex for an individual measurement (normal range is -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.
| Standard deviation score | Early Treated | Early Untreated |
|---|---|---|
| Age 10 (n=32, 30) | -0.66 ± 1.16 | -1.28 ± 1.17 |
| Age 13 (n=29, 29) | -1.29 ± 1.24 | -1.87 ± 1.16 |
| Age 16 (n=18, 18) | -1.66 ± 1.11 | -1.69 ± 1.30 |
The Tanner 2 breast development is the age at first evidence of breast development.
| years | Early Treated | Early Untreated |
|---|---|---|
| Age at Attainment of Tanner 2 Breast Development | 11.80 ± 0.26 | 12.14 ± 0.31 |
Bone age was measured by standard radiograph, x-ray at baseline and annually for 10 years or until attainment of height velocity less than or equal to 1.0 centimeter per year (cm/year) and bone age greater or equal to 15 years.
| years | Early Treated | Early Untreated |
|---|---|---|
| Chronological Age at First Visit Participant Attained Bone Age of 14.5 Years | 14.64 ± 0.25 | 15.26 ± 0.23 |
Number of serious adverse events (SAEs) reported. Any adverse event from this study that results in one of the following outcomes, or is significant for any other reason were reported as an SAE: death, initial or prolonged inpatient hospitalization, a life-threatening experience (that is, immediate risk of dying), persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of a study subject, significant for any other reason (includes cancer, other than superficial, and basal cell or squamous cell carcinomas of the skin, that did not meet other serious adverse event criteria). A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.
| events | Early Treated | Early Untreated |
|---|---|---|
| Reports of Serious Adverse Events | 8 | 5 |
Percentage of participants for whom certain non-serious, pre-specified adverse events (AEs; those that are commonly observed in Turner syndrome or are known to be related to GH treatment: impaired glucose tolerance, diabetes mellitus, hypothyroidism, benign intracranial hypertension, scoliosis, slipped capital femoral epiphysis, solid tumor/leukemia, pancreatitis, ear infections, and high blood pressure) are reported.
| percentage of participants | Early Treated | Early Untreated |
|---|---|---|
| Baseline Ear infections | 13.9 | 18.2 |
| Baseline High Blood Pressure | 0 | 3.0 |
| Baseline Hypothyroidism | 13.9 | 6.1 |
| Baseline Scoliosis | 22.2 | 9.1 |
| Year 1 Ear infections | 38.9 | 39.4 |
| Year 1 High Blood Pressure | 0 | 3.0 |
| Year 1 Hypothyroidism | 11.1 | 12.1 |
| Year 1 Scoliosis | 16.7 | 21.2 |
| Year 2 Diabetes | 2.8 | 0 |
| Year 2 Dilatation of the Aorta | 0 | 3.0 |
| Year 2 Ear infections | 33.3 | 27.3 |
| Year 2 High Blood Pressure | 0 | 3.0 |
| Year 2 Hypothyroidism | 11.1 | 12.1 |
| Year 2 Scoliosis | 22.2 | 24.2 |
| Year 3 Diabetes | 2.8 | 0 |
| Year 3 Dilatation of the Aorta | 0 | 6.1 |
| Year 3 Ear infections | 30.6 | 36.4 |
| Year 3 High Blood Pressure | 0 | 3.0 |
| Year 3 Hypothyroidism | 11.1 | 12.1 |
| Year 3 Scoliosis | 25.0 | 27.3 |
| Year 4 Diabetes | 2.8 | 0 |
| Year 4 Dilatation of the Aorta | 0 | 6.1 |
| Year 4 Ear infections | 16.7 | 30.3 |
| Year 4 High Blood Pressure | 0 | 3.0 |
| Year 4 Hypothyroidism | 11.1 | 12.1 |
| Year 4 Scoliosis | 25.0 | 27.3 |
| Year 5 Diabetes | 2.8 | 0 |
| Year 5 Dilatation of the Aorta | 0 | 6.1 |
| Year 5 Ear infections | 22.2 | 27.3 |
| Year 5 High Blood Pressure | 0 | 3.0 |
| Year 5 Hypothyroidism | 13.9 | 18.2 |
| Year 5 Scoliosis | 25.0 | 27.3 |
| Year 6 Diabetes | 2.8 | 0 |
| Year 6 Dilatation of the Aorta | 0 | 9.1 |
| Year 6 Ear infections | 19.4 | 24.2 |
| Year 6 High Blood Pressure | 0 | 3.0 |
| Year 6 Hypothyroidism | 13.9 | 18.2 |
| Year 6 Scoliosis | 16.7 | 30.3 |
| Year 7 Diabetes | 2.8 | 0 |
| Year 7 Dilatation of the Aorta | 0 | 9.1 |
| Year 7 Ear infections | 19.4 | 18.2 |
| Year 7 High Blood Pressure | 0 | 3.0 |
| Year 7 Hypothyroidism | 13.9 | 15.2 |
| Year 7 Scoliosis | 13.9 | 30.3 |
| Year 8 Diabetes | 2.8 | 0 |
| Year 8 Dilatation of the Aorta | 2.8 | 9.1 |
| Year 8 Ear infections | 13.9 | 18.2 |
| Year 8 High Blood Pressure | 0 | 3.0 |
| Year 8 Hypothyroidism | 5.6 | 12.1 |
| Year 8 Scoliosis | 13.9 | 33.3 |
| Year 9 Dilatation of the Aorta | 0 | 3.0 |
| Year 9 Ear infections | 2.8 | 3.0 |
| Year 9 High Blood Pressure | 0 | 3.0 |
| Year 9 Hypothyroidism | 2.8 | 6.1 |
| Year 9 Scoliosis | 5.6 | 9.1 |
| Year 10 Scoliosis | 2.8 | 0 |
Percentage of participants with abnormal tympanometry \[defined as middle ear dysfunction / middle ear effusion / patent pressure equalizer tube or possible tympanic membrane perforation\] results at baseline, age 10 years, and age 16 years or endpoint.
| percentage of participants | Early Treated | Early Untreated |
|---|---|---|
| Baseline Right Ear | 44.4 | 54.5 |
| Baseline Left Ear | 47.2 | 45.5 |
| Age 10 Right Ear | 27.8 | 15.2 |
| Age 10 Left Ear | 27.8 | 15.2 |
| Age 16 Right Ear | 2.8 | 9.1 |
| Age 16 Left Ear | 2.8 | 3.0 |
| Endpoint Right Ear | 8.3 | 12.1 |
| Endpoint Left Ear | 11.1 | 9.1 |
Percentage of participants with abnormal Audiometry results at baseline, age 10 years, and age 16 years or endpoint. Prevalence was calculated as number of participants with abnormal hearing divided by number of participants with measurable pure tone audiometry results at that visit.
| percentage of participants | Early Treated | Early Untreated |
|---|---|---|
| Baseline Visit (n=36, 33) | 52.8 | 48.5 |
| Age 10 (n=27, 24) | 44.4 | 29.2 |
| Age 16 (n=7, 9) | 85.7 | 66.7 |
| Endpoint (n=24, 22) | 37.5 | 40.9 |
Percentage of participants with abnormal Audiometry results at baseline, age 10 years, and age 16 years or endpoint. PTA is defined as the average of pure tone hearing thresholds at 500, 1000 and 2000 Hz (Hertz), calculated separately for each ear and for each testing method (air or bone); normal PTA is defined as pure tone hearing threshold less than or equal to 20 dB HL (decibels Hearing Level), and abnormal PTA is defined as pure tone hearing threshold greater than 20 DB HL.
| percentage of participants | Early Treated | Early Untreated |
|---|---|---|
| Baseline Left Ear Air (n=36, 32) | 30.6 | 31.3 |
| Baseline Left Ear Bone (n=36, 32) | 2.8 | 0.0 |
| Baseline Right Ear Air (n=36, 32) | 22.2 | 37.5 |
| Baseline Right Ear Bone (n=36, 32) | 22.2 | 2.8 |
| Age 10 Left Ear Air (n=27, 21) | 29.6 | 14.3 |
| Age 10 Left Ear Bone (n=27, 21) | 0.0 | 0.0 |
| Age 10 Right Ear Air (n=27, 22) | 14.8 | 18.2 |
| Age 10 Right Ear Bone (n=27, 22) | 0.0 | 9.1 |
| Age 16 Left Ear Air (n=7, 9) | 57.1 | 66.7 |
| Age 16 Left Ear Bone (n=7, 9) | 0.0 | 0.0 |
| Age 16 Right Ear Air (n=7, 9) | 28.6 | 33.3 |
| Age 16 Right Ear Bone (n=7, 9) | 0.0 | 22.2 |
| Endpoint Left Ear Air (n=20, 20) | 30.0 | 35.0 |
| Endpoint Left Ear Bone (n=20, 20) | 5.0 | 20.0 |
| Endpoint Right Ear Air (n=20, 20) | 20.0 | 35.0 |
| Endpoint Right Ear Bone (n=20, 20) | 10.0 | 25.0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Early Treated | — | 6/36 (16.7%) | 34/36 (94.4%) |
| Early Untreated | — | 5/33 (15.2%) | 32/33 (97%) |
| Event | Early Treated | Early Untreated |
|---|---|---|
| ScoliosisMusculoskeletal and connective tissue disorders | 2/36 | 0/33 |
| Anomalous pulmonary venous connectionCongenital, familial and genetic disorders | 0/36 | 1/33 |
| Pterygium colliCongenital, familial and genetic disorders | 0/36 | 1/33 |
| CellulitisInfections and infestations | 0/36 | 1/33 |
| Lobar pneumoniaInfections and infestations | 0/36 | 1/33 |
| PneumoniaInfections and infestations | 0/36 | 1/33 |
| Atrial septal defectCongenital, familial and genetic disorders | 1/36 | 0/33 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/36 | 0/33 |
| GastroenteritisInfections and infestations | 1/36 | 0/33 |
| MedulloblastomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/36 | 0/33 |
| Event | Early Treated | Early Untreated |
|---|---|---|
| Otitis mediaInfections and infestations | 9/36 | 12/33 |
| VomitingGastrointestinal disorders | 12/36 | 3/33 |
| PyrexiaGeneral disorders | 11/36 | 8/33 |
| Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 11/36 | 9/33 |
| HeadacheNervous system disorders | 11/36 | 9/33 |
| ScoliosisMusculoskeletal and connective tissue disorders | 7/36 | 10/33 |
| Pharyngitis streptococcalInfections and infestations | 4/36 | 9/33 |
| Orthodontic appliance userSocial circumstances | 9/36 | 7/33 |
| Corrective lens userSocial circumstances | 3/36 | 8/33 |
| NasopharyngitisInfections and infestations | 8/36 | 4/33 |
All enrolled/started participants.
| Age, Continuous(years) | Early Treated | Early Untreated | Total |
|---|---|---|---|
| Mean | 8.29 ± 1.22 | 8.41 ± 1.30 | 8.35 ± 1.25 |
| Sex: Female, Male(Participants) | Early Treated | Early Untreated | Total |
|---|---|---|---|
| Female | 36 | 33 | 69 |
| Male | 0 | 0 | 0 |
| Height(centimeter) | Early Treated | Early Untreated | Total |
|---|---|---|---|
| Mean | 124.34 ± 10.08 | 121.06 ± 9.76 | 122.77 ± 9.99 |
| Height Standard Deviation Score (SDS)(Standard Deviation Score) | Early Treated | Early Untreated | Total |
|---|---|---|---|
| Mean | -0.84 ± 1.22 | -1.48 ± 1.23 | -1.15 ± 1.26 |
| Bone Age(years) | Early Treated | Early Untreated | Total |
|---|---|---|---|
| Mean | 8.73 ± 1.55 | 8.34 ± 1.57 | 8.54 ± 1.56 |
The record gives a start of Dec 2005, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2016, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone